Rocket Lab's Neutron Rocket Slips to 2027 After Fuel-Dome Defect, Triggering a Wall Street Recalibration
Published on 10/17/2026 at 12:50 | Editorial boerse-global.de
Rocket Lab has pushed the maiden flight of its Neutron launch vehicle into 2027, abandoning an earlier target of the fourth quarter of 2026 after discovering a manufacturing flaw in the carbon-fibre composite structure of the first stage's fuel dome. The disclosure, filed with the U.S. Securities and Exchange Commission on Form 8-K and accompanied by a development-status presentation, landed midweek and set off an immediate sell-off. By Friday the stock had shed 8.2 percent to close at €45.25.
The company said it has identified and corrected the defect and is now proceeding with improved manufacturing processes. Markets, however, focused on the calendar. Neutron is not merely another rocket in Rocket Lab's lineup — it is the vehicle meant to carry the company into heavier payload classes. Every month the debut slips extends the stretch in which the programme consumes capital without generating operating revenue, pushing the payoff from its hefty development spending further into the future.
A Week to Forget
The damage extends well beyond Friday's session. Over seven days the shares fell 26 percent, and at Friday's close the stock sat 66 percent below its 52-week high of €133.80. Reuters reported that the Neutron announcement was the decisive catalyst behind the immediate declines.
Should investors sell immediately? Or is it worth buying Rocket Lab?
The Street Trims — but Doesn't Retreat
Analysts moved quickly, though their revisions tell a more nuanced story than the price action alone. On Thursday, Goldman Sachs' Noah Poponak cut his price target to $67 from $75 while keeping a neutral "Hold" rating, pointing to the additional spending and higher cash burn implied by the revised Neutron schedule. KeyBanc's Michael Leshock went further on the target, slashing his to $100 from $135, but maintained an "Overweight" rating on the same grounds.
Citizens followed with a reduction to $90 from $130, retaining its "Market Outperform" stance and linking the change directly to the delayed introduction of Neutron and its effect on future launch monetisation. TD Cowen had already moved on 9 October, trimming its target to $90 from $120 in a preview of the third quarter while leaving its "Buy" recommendation untouched.
The pattern across all four houses is consistent: sharply lower targets, unchanged positive ratings. That split captures the dilemma facing observers — the long-term market opportunity remains intact, but the road to it now looks longer and more expensive. When a capital-intensive programme has to run extra loops in manufacturing, the hit to liquidity is direct, and higher costs paired with deferred revenue force analysts to calibrate valuation models more defensively. Confidence in a swift path to profitability has taken a knock.
A Test of Patience
For now, the news flow argues against a quick recovery. The revised timeline and the cash drain it implies are likely to weigh on sentiment around the stock, and the near-term risks lean toward a drawn-out bottoming process as the financial knock-on costs press on the balance sheet. Anyone holding the shares or considering an entry will need patience above all: the case is likely to strengthen only once the process improvements prove themselves and the path toward 2027 is credibly secured. Until then, the timing of the Neutron programme remains the single factor that will define Rocket Lab's medium-term prospects.
Ad
Rocket Lab Stock: New Analysis - 17 October
Fresh Rocket Lab information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
